CYTOGENETICS AND BIOCHEMISTRY OF PROSTATE CANCER

前列腺癌的细胞遗传学和生物化学

• 批准号: 6475794
• 负责人: THOMAS G PRETLOW
• 金额: $ 37.88万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-07-23 至 2003-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6475794
• 关键词: JAK kinase; athymic mouse; biological signal transduction; cell growth regulation; cell line; cellular oncology; cellular pathology; cytogenetics; cytokine receptors; human tissue; mass tissue /cell culture; matrigel; molecular oncology; neoplasm /cancer genetics; neoplasm /cancer transplantation; neoplastic cell; neoplastic growth; prostate neoplasms; prostate specific antigen; protein tyrosine kinase; xenotransplantation

This is a competitive renewal application for CA57179, a grant that was funded for the past 4 years and three months as the result of an RFA related to prostate cancer (PCA). Currently, this grant supports a collaborative effort among faculty interested in cytogenetics, molecular biology, pathology, and urology. The renewal application represents a continued pursuit of selected previous goals. The focus of this study is the use of PCA tissues derived from surgery (a) to attempt to define the factors that control the growth of PCAs and may cause the marked differences in aggressiveness observed in different patients and (b) to use the information derived from these studies and from other laboratories to devise conditions that will permit us to grow PCAs from tissues resected from most PCA patients. Until recently, most PCA work in research laboratories has relied on three cell lines: PC-3, DU 145, and LNCaP. Two of these lines, PC-3 and DU 145, lack evidence of functioning androgen receptors and fail to make prostate specific antigen, quantitatively the most abundant protein product of prostatic epithelial cells. While a few other models of PCA have been developed, they are (a) not generally available and (b) still very limited in their reflection of the broad spectrum of disease seen in PCA. Little is understood about the control of growth in PCA. The usually lengthy (5-20 years) survival of patients with PCA makes PCA a disease in which the ability to grow the tumors of individual patients might have unusual long-term translational significance. If we are able to achieve our goals, this approach might make it possible to develop knowledge of specific patients tumors that would facilitate a more specifically targeted approach to gene therapy, therapy directed against specific tyrosine kinases, antineoplastic chemotherapy, and immunotherapy. The long survival of these patients might allow one to refine these approaches to specific tumors before patients experience the protracted and severe bone pain that afflicts the majority of patients whose deaths are caused by prostate cancer.

这是CA 57179的竞争性续期申请，该补助金 在过去的4年零3个月里， 前列腺癌（PCA） 目前，该基金支持一个 对细胞遗传学、分子遗传学感兴趣的教师之间的协作努力 生物学病理学和泌尿学 续期申请代表 继续追求先前选定的目标。 本研究的重点 是使用来自手术的PCA组织（a）试图定义 控制PCA生长的因素，并可能导致显着的 在不同患者中观察到的攻击性差异，以及（B）至 使用这些研究和其他研究中获得的信息， 实验室设计的条件，将允许我们生长PCA从 从大多数PCA患者身上切除的组织。 直到最近，大多数PCA工作 在研究实验室中依赖于三种细胞系：PC-3，DU 145， 和LNCaP。 其中两条生产线，PC-3和DU 145， 雄激素受体的功能，并未能使前列腺特异性 抗原，前列腺最丰富的蛋白质产物 上皮细胞 虽然已经开发了一些其他的PCA模型， 它们（a）不是普遍可用的，并且（B）在它们的 反映了PCA中所见的广泛疾病。 之甚少 了解对五氯苯甲醚生长的控制。 通常冗长的 (5-20 PCA患者的存活率使PCA成为一种疾病， 个体患者的肿瘤生长能力可能具有不寻常的 长期的翻译意义。 如果我们能够实现我们的 目标，这种方法可能使人们了解 特定患者的肿瘤，这将有助于更具体地 基因治疗的靶向方法，针对特定 酪氨酸激酶、抗肿瘤化疗和免疫治疗。 的 这些患者的长期生存可能使人们能够完善这些 在患者经历长期的 和严重的骨痛折磨着大多数病人， 是由前列腺癌引起的